McDermott Will & Schulte advises WhiteLab Genomics on its $26 million series B financing

McDermott Will & Schulte advised WhiteLab Genomics, a TechBio company using artificial intelligence to design next-generation genomic medicines, on its $26 million Series B financing round.

The round was led by AVP, with participation from new investors Yaday Health and Blast Club, alongside existing shareholders Omnes Capital and Debiopharm Innovation Fund.

This transaction marks a new step in WhiteLab Genomics’ development. It will enable the company to accelerate its in vivo validation programs across viral and non-viral delivery technologies and programmable payloads, and to expand its commercial operations in North America, Europe and Asia.

The McDermott Will & Schulte team alongside WhiteLab Genomics was composed of

• In Paris: Emmanuelle Trombe, partner, and Natacha Vasak, associate, for Life Sciences and Corporate aspects ;
• In Boston: Brian Bunn, partner, for Corporate aspects.